Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912102267> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2912102267 abstract "650 Background: Fluoropyrimidines (FU) are part of chemotherapy combinations for multiple gastrointestinal cancers. Deficient dihydropyrimidine deshydrogenase (DPD) activity can lead to severe life-threatening toxicities in 3-5% of populations tested. The DPYD*2A polymorphism leading to deficient DPD activity is one of the most studied variants. Methods: We retrospectively performed chart reviews of all patients that tested positive for a heterozygous or homozygous DPYD*2A mutation in samples obtained from patients throughout the province of Quebec (Canada). The study objective was to document the impact of implementing this test in routine clinical practice, including the effects on treatment types, delays and toxicities. Results: 2,617 patients were tested by PCR for the presence of DPYD*2A in a period of 17 months: 25 patients tested positive. All were Caucasian. 24 of the 25 patients were heterozygous (0.92%) and one was homozygous (0.038%). A chart review was available for 20 patients: 15 were tested upfront while five were performed following severe toxicities on the first cycle of FU-based chemotherapy. Of the five patients identified following toxicities, all had grade 4 cytopenias, 80% grade ≥ 3 mucositis, 20% grade 3 rash and 20% grade 3 diarrhea, with an average of 15 days of hospitalisations due to febrile neutropenia. Seven of the 13 patients identified upfront received FU-based chemotherapy at reduced initial doses ranging from 25 to 50%. The average dose during the course of chemotherapy was 50% and two patients reached 100% dosage. No grade ≥ 3 toxicities were observed. DPYD*2A test results were available in an average of 6 days, causing no significant delays in treatment initiation according to 99% of queried physicians. Conclusions: Upfront genotyping before FU-based treatment is feasible in clinical practice. It may prevent severe toxicities and hospitalisations without delaying treatment initiation. The administration of chemotherapy at reduced doses appears to be safe in patients heterozygous for DPYD*2A." @default.
- W2912102267 created "2019-02-21" @default.
- W2912102267 creator A5000120535 @default.
- W2912102267 creator A5000594693 @default.
- W2912102267 creator A5008088780 @default.
- W2912102267 creator A5018835840 @default.
- W2912102267 creator A5020900490 @default.
- W2912102267 creator A5027454366 @default.
- W2912102267 creator A5032279767 @default.
- W2912102267 creator A5034580946 @default.
- W2912102267 creator A5038106718 @default.
- W2912102267 creator A5040194713 @default.
- W2912102267 creator A5045449197 @default.
- W2912102267 creator A5064078958 @default.
- W2912102267 creator A5065090308 @default.
- W2912102267 creator A5065265203 @default.
- W2912102267 creator A5067138875 @default.
- W2912102267 creator A5071219496 @default.
- W2912102267 creator A5075835036 @default.
- W2912102267 creator A5090920989 @default.
- W2912102267 date "2019-02-01" @default.
- W2912102267 modified "2023-10-02" @default.
- W2912102267 title "Implementing DPYD*2A genotyping in clinical practice, the Quebec experience." @default.
- W2912102267 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.650" @default.
- W2912102267 hasPublicationYear "2019" @default.
- W2912102267 type Work @default.
- W2912102267 sameAs 2912102267 @default.
- W2912102267 citedByCount "1" @default.
- W2912102267 countsByYear W29121022672022 @default.
- W2912102267 crossrefType "journal-article" @default.
- W2912102267 hasAuthorship W2912102267A5000120535 @default.
- W2912102267 hasAuthorship W2912102267A5000594693 @default.
- W2912102267 hasAuthorship W2912102267A5008088780 @default.
- W2912102267 hasAuthorship W2912102267A5018835840 @default.
- W2912102267 hasAuthorship W2912102267A5020900490 @default.
- W2912102267 hasAuthorship W2912102267A5027454366 @default.
- W2912102267 hasAuthorship W2912102267A5032279767 @default.
- W2912102267 hasAuthorship W2912102267A5034580946 @default.
- W2912102267 hasAuthorship W2912102267A5038106718 @default.
- W2912102267 hasAuthorship W2912102267A5040194713 @default.
- W2912102267 hasAuthorship W2912102267A5045449197 @default.
- W2912102267 hasAuthorship W2912102267A5064078958 @default.
- W2912102267 hasAuthorship W2912102267A5065090308 @default.
- W2912102267 hasAuthorship W2912102267A5065265203 @default.
- W2912102267 hasAuthorship W2912102267A5067138875 @default.
- W2912102267 hasAuthorship W2912102267A5071219496 @default.
- W2912102267 hasAuthorship W2912102267A5075835036 @default.
- W2912102267 hasAuthorship W2912102267A5090920989 @default.
- W2912102267 hasConcept C104317684 @default.
- W2912102267 hasConcept C126322002 @default.
- W2912102267 hasConcept C135763542 @default.
- W2912102267 hasConcept C141071460 @default.
- W2912102267 hasConcept C143998085 @default.
- W2912102267 hasConcept C185592680 @default.
- W2912102267 hasConcept C2776694085 @default.
- W2912102267 hasConcept C2777063308 @default.
- W2912102267 hasConcept C2778496288 @default.
- W2912102267 hasConcept C2778570526 @default.
- W2912102267 hasConcept C2779655350 @default.
- W2912102267 hasConcept C2779802037 @default.
- W2912102267 hasConcept C31467283 @default.
- W2912102267 hasConcept C55493867 @default.
- W2912102267 hasConcept C55775858 @default.
- W2912102267 hasConcept C71924100 @default.
- W2912102267 hasConcept C90924648 @default.
- W2912102267 hasConceptScore W2912102267C104317684 @default.
- W2912102267 hasConceptScore W2912102267C126322002 @default.
- W2912102267 hasConceptScore W2912102267C135763542 @default.
- W2912102267 hasConceptScore W2912102267C141071460 @default.
- W2912102267 hasConceptScore W2912102267C143998085 @default.
- W2912102267 hasConceptScore W2912102267C185592680 @default.
- W2912102267 hasConceptScore W2912102267C2776694085 @default.
- W2912102267 hasConceptScore W2912102267C2777063308 @default.
- W2912102267 hasConceptScore W2912102267C2778496288 @default.
- W2912102267 hasConceptScore W2912102267C2778570526 @default.
- W2912102267 hasConceptScore W2912102267C2779655350 @default.
- W2912102267 hasConceptScore W2912102267C2779802037 @default.
- W2912102267 hasConceptScore W2912102267C31467283 @default.
- W2912102267 hasConceptScore W2912102267C55493867 @default.
- W2912102267 hasConceptScore W2912102267C55775858 @default.
- W2912102267 hasConceptScore W2912102267C71924100 @default.
- W2912102267 hasConceptScore W2912102267C90924648 @default.
- W2912102267 hasLocation W29121022671 @default.
- W2912102267 hasOpenAccess W2912102267 @default.
- W2912102267 hasPrimaryLocation W29121022671 @default.
- W2912102267 hasRelatedWork W1963790758 @default.
- W2912102267 hasRelatedWork W2018766079 @default.
- W2912102267 hasRelatedWork W2202643944 @default.
- W2912102267 hasRelatedWork W2571275567 @default.
- W2912102267 hasRelatedWork W2906078103 @default.
- W2912102267 hasRelatedWork W2913296433 @default.
- W2912102267 hasRelatedWork W3032088737 @default.
- W2912102267 hasRelatedWork W3125862781 @default.
- W2912102267 hasRelatedWork W3200469478 @default.
- W2912102267 hasRelatedWork W4210257644 @default.
- W2912102267 isParatext "false" @default.
- W2912102267 isRetracted "false" @default.
- W2912102267 magId "2912102267" @default.
- W2912102267 workType "article" @default.